Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC
The proposed model based on radiomic signature helps to evaluate PD-1 status of HCC patients and may be used for evaluating patients most likely to benefit from sorafenib as a potentially combination therapy regimen with immune checkpoint therapies.
Authors
- Xin Zhang (ORCID: https://orcid.org/0000-0001-6668-0289)
- Ailin Liang (ORCID: https://orcid.org/0000-0003-1240-7185)
- Feng Che
- Bin Song (ORCID: https://orcid.org/0000-0002-7269-2101)
- Yuan Yuan (ORCID: https://orcid.org/0000-0001-9974-0516)
- Yi Wei (ORCID: https://orcid.org/0000-0002-4620-2121)
- Qing Xu (ORCID: https://orcid.org/0000-0001-9817-302X)
- Qian Li (ORCID: https://orcid.org/0009-0008-1104-1816)
- Zhou Wang
- Gulizaina Hapaer
- Jituome Ziluo
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Sanya Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-01-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1435668
- Citations
- 5
- Primary Topic
- Radiomics and Machine Learning in Medical Imaging
- Type
- article
- Field-Weighted Citation Impact
- 6.80
Funders
- National Natural Science Foundation of China
- Sichuan University
- West China Hospital, Sichuan University